FreeStyle Libre system associated with reduction in HbA1c levels for type 2 diabetes.- Abbott

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, continuous glucose monitoring (CGM) technology, is associated with significant reduction in hemoglobin A1c (HbA1c) levels for people living with type 2 diabetes on either long-acting insulin or non-insulin therapy.

These results are similar to outcomes typically seen when adding insulin therapy to treatment regimens,4 indicating people may be able to manage their glucose levels with CGM technology instead of adding insulin. In an observational, retrospective study (Abstract 84-LB)1 researchers assessed changes in HbA1c levels in people with type 2 diabetes who were either on long-acting insulin or non-insulin therapy. They analyzed HbA1c levels from baseline to six months and baseline to 12 months after initiating use of the FreeStyle Libre system.

The results demonstrated overall lower HbA1c levels associated with the use of Abbott’s technology, specifically a 0.8% drop after six months (from 8.5% to 7.7%) and 0.6% drop after one year of FreeStyle Libre system use (from 8.5% to 7.9%) – clinically significant reductions of average glucose levels over time toward the ADA’s recommended A1c goal of 7% for adults with diabetes.5 Additional notable findings showed the greatest HbA1c decreases occurred among the non-insulin users with type 2 diabetes, including a 0.9% reduction at six months and 0.7% drop after 12 months. Among those people with type 2 diabetes on long-acting insulin, HbA1c reductions were 0.6% and 0.5% at six and 12 months, respectively. The real-world data were presented as a late-breaking abstract at the American Diabetes Association (ADA) 80th Scientific Sessions.